OPKO HEALTH INC. - CO

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

25 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

OPKO Health to Present at the 2022 Jefferies Healthcare Conference

02 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

09 May 2022 15:05:01 By Nasdaq GlobeNewswire

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

09 May 2022 08:23:34 By Nasdaq GlobeNewswire

OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

05 May 2022 15:05:02 By Nasdaq GlobeNewswire

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

24 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

17 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

03 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

20 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

23 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

08 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Announces the Passing of Director Dr. Richard Lerner

06 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

29 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

28 Oct 2021 15:15:01 By Nasdaq GlobeNewswire

OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

25 Oct 2021 09:57:14 By Nasdaq GlobeNewswire

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

24 Sep 2021 15:24:07 By Nasdaq GlobeNewswire

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories

14 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

30 Aug 2021 15:17:19 By Nasdaq GlobeNewswire

OPKO Health to Participate in Two Upcoming Investment Conferences

30 Aug 2021 08:04:49 By Nasdaq GlobeNewswire

OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

29 Jul 2021 15:05:01 By Nasdaq GlobeNewswire